NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
This NCCN Task Force Report describes the management of dermatologic and ocular toxicities that occur in patients treated with epidermal growth factor receptor (EGFR) inhibitors. Task force members are from NCCN member institutions and include oncologists, dermatologists, an ophthalmologist, and a mid-level oncology provider. This report describes commonly used therapies that the task force agreed are appropriate standards of care for dermatologic and ophthalmologic toxicities associated with EGFR inhibitors, which generally are supported only by anecdotal evidence. Few recommendations are evidence based; however, some commonly used therapies have data supporting their use. Conclusions from completed clinical trials are generally limited by the small numbers of patients enrolled. The information in this report is based on available published data on treating toxicities associated with EGFR inhibitors, data from treatment of clinically similar toxicities from different etiologies, and expert opinion among the NCCN Task Force members.
Burtness
Barbara
B
Fox Chase Cancer Center, USA.
Anadkat
Milan
M
Basti
Surendra
S
Hughes
Miranda
M
Lacouture
Mario E
ME
McClure
Joan S
JS
Myskowski
Patricia L
PL
Paul
Jennifer
J
Perlis
Clifford S
CS
Saltz
Leonard
L
Spencer
Sharon
S
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005128:Eye Diseases / Q000139:chemically induced; D006201:Hair Diseases / Q000139:chemically induced; D006801:Humans; D009260:Nail Diseases / Q000139:chemically induced; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects; D012871:Skin Diseases / Q000139:chemically induced*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors